The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
 
Maliheh Mohamadpour
No Relationships to Disclose
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron (Inst)
 
Anuja Kriplani
No Relationships to Disclose
 
James Vincent Fetten
No Relationships to Disclose
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune; Seagan; Seagan
 
Loren S. Michel
Consulting or Advisory Role - KisoJi Biotechnology
Research Funding - Exelixis (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Kin Wai (Tony) Hung
Stock and Other Ownership Interests - TeamX Medical Group
Patents, Royalties, Other Intellectual Property - LookUpTrials - Patent pending
 
Shrujal S. Baxi
Employment - Flatiron Health; Iterative Health; Verana Health
Stock and Other Ownership Interests - Roche
 
Erin McDonald
No Relationships to Disclose
 
Rachel Conybeare
No Relationships to Disclose
 
Nora Katabi
No Relationships to Disclose
 
Irina Ostrovnaya
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Incyte; MeiraGTx; Nykode Therapeutics
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Alan Loh Ho
Stock and Other Ownership Interests - Rgenta
Honoraria - Endocrine Society; Physicans' Education Resource
Consulting or Advisory Role - AffyImmune Therapeutics; Ayala Pharmaceuticals; Cellestia Biotech; Eisai; Eisai; Elevar Therapeutics; Exelixis; ExpertConnect; InxMed; Kura Oncology; Merck; Prelude Therapeutics; Remix Therapeutics; Rgenta
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Kura Oncology; Merck; Novartis
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN